Products
News
Resources
Contact
Language
简体中文
繁體中文
English
日本語
한국어
Tiếng Việt
Overview
Latest
Regional
Industry
Featured
Multimedia
Other Languages
Public Company News
All
APAC
Global
All
APAC
Global
All
APAC
Global
All
APAC
Global
{{toptitleLeft}}
{{toptitleRight}}
{{selectTitle}}
{{toptitleLeft}}
{{index}}
{{select_list_per.name}}
Time
{{showName}}
{{weixin_name}}
X
{{listname}}
Loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.headline}}
{{storydata.create_time}}
{{storydata.headline}}
{{storydata.create_time}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
loading
The End
Network Errors Please Retry
Qiming's Portfolio Company InventisBio Lists on STAR Market
2022-07-25 11:55
Qiming's Portfolio Company InventisBio Lists on STAR Market
2022-07-25 11:55
Qiming Venture Partners Announces Closing of Funds Totaling US$3.2 Billion
2022-07-11 09:00
CanSinoBIO's COVID-19 Vaccine Convidecia™ Receives WHO Emergency Use Listing
2022-05-19 23:28
CanSinoBIO Rebrands to Reflect Commitment to Life Sciences Research
2022-04-25 08:00
Qiming's Nisa Leung, Duane Kuang Named on 2022 Forbes Midas List
2022-04-13 09:20
CanSinoBIO's COVID-19 mRNA Vaccine Receives Approval of Clinical Trial Application in China
2022-04-04 08:30
CanSinoBIO's Convidecia™ Approved as Heterologous Booster in Malaysia and Indonesia
2022-03-22 21:32
Latest Study Shows Advantages of CanSinoBIO's Convidecia™ as Heterologous Booster against Omicron Variant
2022-03-14 08:00
CanSinoBIO's Convidecia™ Approved as Heterologous Booster in China
2022-02-21 08:05
Latest Study Shows Encouraging Results of CanSinoBIO's Inhaled COVID-19 Vaccine as Heterologous Booster
2022-01-11 15:15
CanSinoBIO Announces Approval for its MCV4 Product Menhycia™ in China
2022-01-09 10:09
Convidecia™ Phase III Results Published in The Lancet
2021-12-24 15:28
CanSinoBIO Receives European GMP Certification for its COVID-19 Vaccine Convidecia™
2021-05-24 17:00
CanSinoBIO Announces Approval for its Single-Dose COVID-19 Vaccine Convidecia™ in Chile
2021-04-08 21:17
CanSinoBIO Announces Approval for its Single-Dose COVID-19 Vaccine Convidecia™ in Hungary
2021-03-23 00:43
CanSinoBIO's Successful Listing on STAR Market Makes it the Initial Dual Listing Vaccine Company
2020-08-13 10:00
CanSino Biologics and Precision NanoSystems Announce Collaboration to Co-Develop a COVID-19 RNA Vaccine
2020-05-20 21:00
1